COVID-19 Vaccine Market - 2024-2033

January 2026 | 200 pages | ID: C842B6813121EN
DataM Intelligence

Abstracts

The COVID-19 Vaccine Market was valued at US$ 13.43 billion in 2024 and is anticipated to reach US$ 29.98 billion by 2033, at a CAGR of 0.098 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the COVID-19 Vaccine Market.

This report delivers a comprehensive overview of the COVID-19 Vaccine Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding COVID-19 Vaccine Market. The COVID-19 Vaccine Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

COVID-19 Vaccine Market Scope:

By Infection Type

• SARS-CoV-2
• HCoVs
• Others

By Vaccine Type

• mRNA Vaccines
• Viral Vector Vaccines
• Inactivated Virus Vaccines
• Protein Subunit Vaccines
• Live Attenuated Vaccines
• Others

By Route of Administration

• Intramuscular
• Subcutaneous
• Oral

By Age Group

• Below 18 Years
• Above 18 Years

By End-User

• Hospitals
• Specialty Clinics
• Others

Key Players

• Pfizer/BioNTech
• Moderna, Inc.
• AstraZeneca.
• Johnson & Johnson (Janssen Scientific Affairs, LLC)
• SINOVAC
• CanSino Biologics Inc.
• Novavax.
• Sanofi/GSK
• Beijing Institute of Biological Products Co., Ltd.
• Serum Institute of India Pvt. Ltd.
• Gamaleya Research Institute

Major Highlights

This report delivers a comprehensive overview of the COVID-19 Vaccine Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding COVID-19 Vaccine Market. The COVID-19 Vaccine Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

• Increase Your Customer Base by 3X using our Partner Identification tool
• Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
• Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
• Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

3.1. Snippet by Infection Type
3.2. Snippet by Vaccine Type
3.3. Snippet by Route of Administration
3.4. Snippet by Age Group
3.5. Snippet by End-User
3.6. Snippet by Region

4. DYNAMICS

4.1. Impacting Factors
  4.1.1. Drivers
    4.1.1.1. Government Support and Initiatives
    4.1.1.2. XX
  4.1.2. Restraints
    4.1.2.1. Limited Manufacturing Capacity
  4.1.3. Opportunity
  4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. BY INFECTION TYPE

6.1. Introduction
  6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  6.1.2. Market Attractiveness Index, By Infection Type
6.2. SARS-CoV-2*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. HCoVs
6.4. Others

7. BY VACCINE TYPE

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  7.1.2. Market Attractiveness Index, By Vaccine Type
7.2. mRNA Vaccines*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Viral Vector Vaccines
7.4. Inactivated Virus Vaccines
7.5. Protein Subunit Vaccines
7.6. Live Attenuated Vaccines
7.7. Others

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  8.1.2. Market Attractiveness Index, By Route of Administration
8.2. Intramuscular*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Subcutaneous
8.4. Oral

9. BY AGE GROUP

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  9.1.2. Market Attractiveness Index, By Age Group
9.2. Below 18 Years*
  9.2.1. Introduction
  9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Above 18 Years

10. BY END-USER

10.1. Introduction
  10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  10.1.2. Market Attractiveness Index, By End-User
10.2. Hospitals *
  10.2.1. Introduction
  10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Specialty Clinics
10.4. Others

11. BY REGION

11.1. Introduction
  11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  11.1.2. Market Attractiveness Index, By Region
11.2. North America
  11.2.1. Introduction
  11.2.2. Key Region-Specific Dynamics
  11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.2.8.1. U.S.
    11.2.8.2. Canada
    11.2.8.3. Mexico
11.3. Europe
  11.3.1. Introduction
  11.3.2. Key Region-Specific Dynamics
  11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.3.8.1. Germany
    11.3.8.2. U.K.
    11.3.8.3. France
    11.3.8.4. Spain
    11.3.8.5. Italy
    11.3.8.6. Rest of Europe
11.4. South America
  11.4.1. Introduction
  11.4.2. Key Region-Specific Dynamics
  11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.4.8.1. Brazil
    11.4.8.2. Argentina
    11.4.8.3. Rest of South America
11.5. Asia-Pacific
  11.5.1. Introduction
  11.5.2. Key Region-Specific Dynamics
  11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    11.5.8.1. China
    11.5.8.2. India
    11.5.8.3. Japan
    11.5.8.4. South Korea
    11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
  11.6.1. Introduction
  11.6.2. Key Region-Specific Dynamics
  11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

13.1. Pfizer/BioNTech*
  13.1.1. Company Overview
  13.1.2. Product Portfolio
    13.1.2.1. Product Description
    13.1.2.2. Product Key Performance Indicators (KPIs)
    13.1.2.3. Historic and Forecasted Product Sales
    13.1.2.4. Product Sales Volume
  13.1.3. Financial Overview
    13.1.3.1. Company Revenue’s
    13.1.3.2. Geographical Revenue Shares
    13.1.3.3. Revenue Forecasts
  13.1.4. Key Developments
    13.1.4.1. Mergers & Acquisitions
    13.1.4.2. Key Product Development Activities
    13.1.4.3. Regulatory Approvals etc.
  13.1.5. SWOT Analysis
13.2. Moderna, Inc.
13.3. AstraZeneca.
13.4. Johnson & Johnson (Janssen Scientific Affairs, LLC)
13.5. SINOVAC
13.6. CanSino Biologics Inc.
13.7. Novavax.
13.8. Sanofi/GSK
13.9. Beijing Institute of Biological Products Co., Ltd.
13.10. Serum Institute of India Pvt. Ltd.
13.11. Gamaleya Research Institute (*LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services
14.2. Contact Us